Deconditioning Hypothesis

ImportantHypothesis: The Deconditioning Narrative as Iatrogenic Harm Multiplier

Certainty: 0.50. The individual components are well-documented (GET harms, deconditioning beliefs among clinicians, delayed diagnosis patterns). The systems-level causal chain linking belief → prescription → harm → worsening is strongly supported by patient surveys (Kindlon 2011) and guideline changes (National Institute for Health and Care Excellence 2021), but has not been tested as a formal causal model with appropriate controls.

This hypothesis proposes that the deconditioning narrative does not merely fail to help ME/CFS patients—it functions as an active disease modifier that worsens long-term outcomes through a specific iatrogenic causal chain:

  • Belief formation: Clinician attributes symptoms to deconditioning based on training, guidelines, or institutional culture.
  • Exercise prescription: Patient is prescribed graded exercise therapy or encouraged to “push through” fatigue.
  • PEM trigger: Exercise exceeds the patient’s energy envelope, triggering post-exertional malaise.
  • Misinterpretation: Crash is interpreted as insufficient effort, psychological resistance, or temporary setback rather than pathological response.
  • Escalation: More exercise is prescribed, or patient internalises the message and pushes harder.
  • Cumulative damage: Repeated PEM episodes cause cumulative deterioration via the ratchet mechanism (Speculation Infection-Induced Irreversible Damage: The Ratchet Model), potentially converting mild–moderate disease to severe.

The hypothesis predicts that the deconditioning belief itself is a measurable disease modifier: patients whose clinicians believe in deconditioning will have worse long-term outcomes than patients whose clinicians recognize PEM, independent of treatment received, because the belief shapes the entire clinical encounter—advice given, symptoms dismissed, investigations not ordered, diagnoses delayed.

Testable Predictions.

  • Retrospective cohort comparison: ME/CFS patients whose medical records document deconditioning-based advice will show greater functional decline over 5 years than patients whose records document PEM-aware management, after controlling for baseline severity and comorbidities.
  • Time-to-diagnosis will be longer in patients initially managed under the deconditioning paradigm.
  • The proportion of patients progressing from mild/moderate to severe will be higher in cohorts managed with GET than in cohorts managed with pacing from onset.
  • Regional variation in GET prescription rates (pre-2021 UK vs. Scandinavian countries that abandoned GET earlier) will correlate with regional rates of severe ME/CFS.

Falsifiability. This hypothesis would be falsified if patients managed under the deconditioning paradigm show equal or better long-term outcomes than patients managed with PEM-aware approaches, after controlling for baseline severity. It would also be weakened if the progression from mild to severe ME/CFS occurs at equal rates regardless of clinical management approach.

Limitations. Retrospective cohort studies cannot fully control for confounders (patients who receive deconditioning-based care may differ systematically from those who receive PEM-aware care). Selection bias is likely: patients who seek PEM-aware clinicians may be more medically literate or have better access to specialist care. A randomized trial would be unethical given existing evidence of GET harm.

The deconditioning hypothesis posits that ME/CFS symptoms are primarily maintained by physical inactivity: patients reduce activity due to fatigue, lose cardiovascular and muscular fitness, and experience worsening symptoms that reinforce further inactivity. Under this model, graded exercise therapy (GET) should reverse the cycle. This hypothesis dominated clinical guidance for decades and underpinned the PACE trial’s exercise arm.

1 Arguments For Deconditioning

ME/CFS patients do show objective markers consistent with deconditioning: reduced VO2peak, lower peak heart rate, and decreased muscle mass in some studies. Prolonged bed rest produces symptoms (orthostatic intolerance, fatigue, cognitive slowing) that overlap with ME/CFS. These parallels led clinicians to assume that reversing inactivity would resolve symptoms.

2 Why Deconditioning Fails as a Primary Explanation

Multiple lines of evidence demonstrate that deconditioning cannot account for the core pathophysiology of ME/CFS:

  • Post-exertional malaise is the hallmark feature. Deconditioned individuals improve with progressive exercise; ME/CFS patients deteriorate. Two-day CPET protocols show reproducible day-2 performance decline in ME/CFS but not in sedentary controls or patients with other fatiguing conditions in positive studies (Keller et al. 2024) (Lim et al. 2020), though a 2026 null replication did not find group-average VO₂ decline (Mancini et al. 2026); elevated RPE and chronotropic incompetence are consistent findings across studies.
  • VO2peak reduction exceeds deconditioning predictions. The NIH deep phenotyping study documented exercise impairment beyond what inactivity alone would produce, even in patients with relatively preserved activity levels (Walitt et al. 2024). Walitt et al. themselves acknowledged that deconditioning is a consequence, not a cause, and that equal maximum grip strength argues against pure deconditioning. In Long COVID with PEM, activity-matching and effort-independent submaximal thresholds further exclude deconditioning ((Appelman et al. 2025); Section Two-Day CPET: Biomarker Utility Limitations).
  • Metabolic dysfunction is cellular, not peripheral. Impaired mitochondrial function in immune cells (Mandarano et al. 2020) and abnormal metabolite profiles persist independently of activity levels (Chapter Energy Metabolism and Mitochondrial Function).
  • Autonomic and immune abnormalities are independent of fitness. Chronotropic incompetence, catecholamine deficiency (Walitt et al. 2024), T cell exhaustion, and NK cell dysfunction are documented in ME/CFS. Chronotropic incompetence can also result from deconditioning — its presence does not discriminate between the two models — but its co-occurrence with catecholamine deficiency and immune abnormalities supports a multisystem pathology beyond deconditioning alone.
  • GET produces harm, not recovery. Large self-reported patient surveys report that 51% of ME/CFS patients worsened with GET (Kindlon 2011). NICE withdrew GET from its 2021 guidelines, declaring it potentially harmful (National Institute for Health and Care Excellence 2021). Charlton et al. (2026), writing in the British Journal of Sports Medicine, directly addressed the deconditioning narrative in the context of long COVID (Charlton et al. 2026). Their editorial—co-authored by Systrom (pioneer of invasive CPET demonstrating preload failure in ME/CFS) and Putrino (leading long COVID researcher at Mount Sinai)—argued that post-exertional malaise cannot be explained by cardiac deconditioning and called for rethinking the pathophysiology of exercise intolerance in post-viral illness. The publication of this argument in a mainstream sports medicine journal marks a significant shift: the deconditioning myth is now being challenged from within the exercise science community itself, not only by ME/CFS specialists and patient advocates.

3 Deconditioning as Secondary Consequence

Deconditioning does occur in ME/CFS—as a consequence of enforced inactivity due to PEM, not as a cause of symptoms. This distinction is clinically critical: treating secondary deconditioning requires activity management within the energy envelope (pacing; Section Pacing and Energy Management), not progressive exercise that violates it. Conflating consequence with cause has caused measurable harm to patients and delayed appropriate treatment (Section Exercise Therapy Debates).

References

Appelman, Brent, Braeden T. Charlton, Richie P. Goulding, Tom J. Kerkhoff, Ellen A. Breedveld, Wendy Noort, Carla Offringa, et al. 2025. “Reply: Muscle Abnormalities in Long COVID.” Nature Communications 16: 1491. https://doi.org/10.1038/s41467-025-56431-7.
Charlton, Braeden T, Kasper Janssen, David M Systrom, David Putrino, and Rob C I Wüst. 2026. “Post-Exertional Malaise and the Myth of Cardiac Deconditioning: Rethinking the Pathophysiology of Long COVID.” British Journal of Sports Medicine. https://doi.org/10.1136/bjsports-2025-111387.
Keller, Betsy A, Candace N Receno, Carl J Franconi, Sebastian Harenberg, Jared Stevens, Xiangling Mao, Staci R Stevens, et al. 2024. “Cardiopulmonary and Metabolic Responses During a 2-Day CPET in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Translating Reduced Oxygen Consumption to Impairment Status to Treatment Considerations.” Journal of Translational Medicine 22 (1): 627. https://doi.org/10.1186/s12967-024-05410-5.
Kindlon, Tom. 2011. “Reporting of Harms Associated with Graded Exercise Therapy and Cognitive Behavioural Therapy in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” Bulletin of the IACFS/ME 19 (2): 59–111.
Lim, Eun-Jin, Eun-Bum Kang, Eun-Su Jang, and Chang-Gue Son. 2020. “Systematic Review of the Two-Day Cardiopulmonary Exercise Test as an Objective Assessment Tool for Post-Exertional Malaise in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” Journal of Clinical Medicine 9 (12): 4040. https://doi.org/10.3390/jcm9124040.
Mancini, Donna M., Dane B. Cook, Danielle L. Brunjes, Tiffany Soto, Michelle Blate, Patrick Quan, Tadahiro Yamazaki, Anna Norweg, and Benjamin H. Natelson. 2026. “Cardiopulmonary Exercise Test Results Do Not Change over Two Sequential Days in Patients with Chronic Fatigue Syndrome.” Frontiers in Physiology 17: 1816082. https://doi.org/10.3389/fphys.2026.1816082.
Mandarano, Alexandra H., Jessica Maya, Ludovic Giloteaux, Daniel L. Peterson, Marco Maynard, C. Gunnar Gottschalk, and Maureen R. Hanson. 2020. “Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients Exhibit Altered t Cell Metabolism and Cytokine Associations.” Journal of Clinical Investigation 130 (3): 1491–1505. https://doi.org/10.1172/JCI132185.
National Institute for Health and Care Excellence. 2021. “Myalgic Encephalomyelitis (or Encephalopathy)/Chronic Fatigue Syndrome: Diagnosis and Management.” NICE guideline [NG206]. https://www.nice.org.uk/guidance/ng206.
Walitt, Brian, Komudi Singh, Samuel R LaMunion, Mark Hallett, Sandra Jacobson, Kong Chen, Yoshihisa Enose-Akahata, et al. 2024. “Deep Phenotyping of Post-Infectious Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” Nature Communications 15 (1): 907. https://doi.org/10.1038/s41467-024-45107-3.